Cite
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
MLA
Leek, Lindsay V. M., et al. “Multi-Omic Analysis Identifies Hypoalbuminemia as Independent Biomarker of Poor Outcome upon PD-1 Blockade in Metastatic Melanoma.” Scientific Reports, vol. 14, no. 1, May 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41598-024-61150-y.
APA
Leek, L. V. M., Notohardjo, J. C. L., de Joode, K., Velker, E. L., Haanen, J. B. A. G., Suijkerbuijk, K. P. M., Aarts, M. J. B., de Groot, J. W. B., Kapiteijn, E., van den Berkmortel, F. W. P. J., Westgeest, H. M., de Gruijl, T. D., Retel, V. P., Cuppen, E., van der Veldt, A. A. M., Labots, M., Voest, E. E., van de Haar, J., & van den Eertwegh, A. J. M. (2024). Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma. Scientific Reports, 14(1), 1–11. https://doi.org/10.1038/s41598-024-61150-y
Chicago
Leek, Lindsay V. M., Jessica C. L. Notohardjo, Karlijn de Joode, Eline L. Velker, John B. A. G. Haanen, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, et al. 2024. “Multi-Omic Analysis Identifies Hypoalbuminemia as Independent Biomarker of Poor Outcome upon PD-1 Blockade in Metastatic Melanoma.” Scientific Reports 14 (1): 1–11. doi:10.1038/s41598-024-61150-y.